The world's first targeted human interleukin-5 antibody biologics approved for marketing, Xin Kelai debuts at the 4th CIIE

Shanghai, November 6, 2021/PRNewswire/ - Today, at the 4th China International Import Expo, Xinkelai (generic name: mepolizumab) became the world's first target approved for marketing The identity of human interleukin-5 (IL-5) antibody biologics was officially unveiled, hoping to provide new treatment options for Chinese patients and families affected by inflammatory diseases caused by eosinophilia

Qi Xin, General Manager of Prescription Drugs and Vaccines of GSK China, said: “The

Speech by Qi Xin, General Manager of GSK China Prescription Drugs and Vaccines

Xin Kelai has been approved in the United States and many other countries around the world for the treatment of inflammatory diseases caused by eosinophilia, including severe eosinophilic asthma (SEA), eosinophilic granulomatous polyangiitis ( EGPA), hypereosinophilic syndrome (HES), and chronic rhinosinusitis with nasal polyps (CRSwNP)

Professor Jiang Lindi from the Department of Rheumatology and Immunology, Zhongshan Hospital Affiliated to Fudan University, pointed out: “Eosinophils are closely related to the occurrence of many diseases in the human body, including EGPA and severe asthma

Jiang Lindi, Department of Rheumatology and Immunology, Zhongshan Hospital, Fudan University, introduced EGPA

Xin Kelai is the world’s first antibody biologic that targets human interleukin-5 (IL-5).

*Mepolizumab has not yet been approved in the Chinese mainland market

About GSK:

GSK is a science-oriented global healthcare company that aims to help people do more, feel more comfortable, and live longer

Source: GSK